Health insurance stocks: UnitedHealth Group, CVS, and Humana are rising on Medicare Advantage news
Health insurance stocks, including those of UnitedHealth Group, Humana, and CVS Health, are increasing after the Trump administration decided to significantly raise Medicare insurer payments. This decision backtracks on an earlier, lower increase proposal and follows extensive lobbying from the private insurance industry. The revised plan means an additional $13 billion will be paid to private health insurers for Medicare Advantage in 2027, with a net average increase of 2.48%.
S&P 500 Futures Decline in Premarket Trading; Valmont Industries, Loews Lag
S&P 500 futures are declining in premarket trading, with specific companies like Valmont Industries and Loews lagging. Conversely, Humana Inc. (HUM) and Brookfield Wealth Solutions Ltd. (BNT) are showing significant gains, up 9.8% and 9.7% respectively, as the U.S. stock markets approach their open. This article provides an early look at market movements before trading begins.
CMS Medicare Rate Decision Reframes UnitedHealth Group Valuation And Risk Profile
The CMS has finalized a 2.48% rate increase for 2027 Medicare Advantage and Part D payments, which is higher than initially expected and provides clarity for UnitedHealth Group, a major Medicare Advantage operator. This decision offers a more supportive baseline for Medicare Advantage profitability, despite ongoing questions about medical costs and competitive pressures. While the company's shares are considered undervalued by Simply Wall St, a flagged risk is UnitedHealth Group's high debt level.
Fulton Breakefield Broenniman LLC Has $14.87 Million Stock Position in UnitedHealth Group Incorporated $UNH
Fulton Breakefield Broenniman LLC reduced its stake in UnitedHealth Group (UNH) by 8.3% in Q4, now holding 45,041 shares valued at $14.87 million. The healthcare conglomerate is experiencing positive sentiment due to a larger-than-expected Medicare Advantage payment increase for 2027, boosting its revenue outlook. Analysts maintain a "Moderate Buy" rating with a target price of $363.38, while the company anticipates Q1 earnings on April 21st.
Insurance stocks jump on Medicare Advantage rate boost: Humana, UnitedHealth, lead gains (UNH:NYSE)
Insurance stocks, including Humana and UnitedHealth, saw increases after the Centers for Medicare & Medicaid Services (CMS) announced a 2.48% boost in average Medicare Advantage payments for 2027, totaling over $13 billion. This positive news led to gains for major insurance companies in after-hours trading.
New Medicare Payment Rate Released. Why UnitedHealth Stock Is Popping.
The federal government has announced a 2.48% average increase in Medicare payments to insurers for next year, a significant financial update for major health insurance companies. This news has led to a rise in UnitedHealth's stock. Medicare Advantage is a crucial business segment for these insurers, covering 35 million beneficiaries.
Elevance (ELV) Shares Surge 6% Following Medicare Payment Update
Elevance (ELV) shares rose 6% after the Centers for Medicare & Medicaid Services (CMS) finalized the 2027 Medicare payment rates, signaling investor confidence. Elevance Health Inc, a major U.S. health insurer with a $66.47 billion market cap, holds a significant presence in government-sponsored programs. Despite a recent earnings decline, its financial health remains stable with attractive valuation metrics suggesting potential undervaluation.
CVS, UnitedHealth, Humana, Elevance Shares Surge: Here's Why
Shares of several major health insurers, including CVS, UnitedHealth, Humana, and Elevance, saw significant after-hours gains on Monday. This surge followed the Centers for Medicare and Medicaid Services (CMS) finalizing payment policies for 2027, projecting a net average increase of 2.48% for Medicare Advantage (MA) and Part D plans. The CMS stated that these updates aim to keep coverage affordable and ensure value for patients.
A Look At Alignment Healthcare (ALHC) Valuation After Earnings Beat And Cautious Revenue Guidance
Alignment Healthcare (ALHC) recently reported strong quarterly results, exceeding revenue and earnings expectations, yet cautious revenue guidance for the next quarter caused an 8.5% stock drop. Despite a significant 3-year shareholder return and an analyst-suggested intrinsic discount, investors are advised to carefully assess if a buying opportunity exists or if the market has already factored in future growth. The company's valuation relies on a narrative of robust technology-enabled care, investments in automation, and improved scalability, but faces risks from Medicare Advantage policy and competitive member growth.
Principal Financial (NYSE: PFG) touts 18% TSR, $1.5B returns in proxy
Principal Financial Group (NYSE: PFG) highlights strong 2025 financial performance in its proxy statement, including an 18% total shareholder return that outperformed the S&P 500 and over $1.5 billion returned to shareholders through repurchases and dividends. The company reported $781 billion in assets under management and $1.8 trillion in assets under administration, with margins expanding to 31%. Shareholders are asked to vote on director elections, executive pay, auditor ratification, and a new stock incentive plan at the upcoming virtual annual meeting on May 19, 2026.
Bronstein, Gewirtz & Grossman, LLC Encourages Elevance Health, Inc. (ELV) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elevance Health, Inc. (NYSE:ELV) securities who bought prior to April 18, 2024, and still hold shares. The law firm is looking into whether Elevance and its officers engaged in corporate wrongdoing. Investors are encouraged to contact the firm for more information on how to assist with the investigation, with no cost to them for engaging Bronstein, Gewirtz & Grossman, LLC.
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of DICK’s Sporting Goods, Inc. (DKS), Domino’s Pizza, Inc. (DPZ), Elanco Animal Health Incorporated (ELAN), and Elevance Health, Inc. (ELV)
Johnson Fistel, PLLP has initiated investigations into potential claims on behalf of long-term shareholders of DICK's Sporting Goods, Domino's Pizza, Elanco Animal Health, and Elevance Health. The investigations focus on alleged breaches of fiduciary duty by officers and directors, stemming from previously filed securities class action complaints. These complaints detail accusations of misleading statements and undisclosed material adverse facts regarding each company's business, operations, and prospects.
Morgan Stanley Lowers Price Target on MetLife to $89 From $93, Keeps Overweight Rating
Morgan Stanley has adjusted its price target for MetLife (MET) to $89, down from the previous $93, while maintaining an "Overweight" rating on the stock. This update reflects a revised valuation perspective from the firm. The article also mentions recent MetLife developments including executive appointments and changes in S&P 100 listing.
Elevance Health Earnings Preview: What to Expect
Elevance Health (ELV) is slated to release its Q1 2026 earnings on April 22, with analysts predicting a profit of $10.61 per share, an 11.4% decrease year-over-year. The company's stock has underperformed, falling 30% over the past 52 weeks, attributed to pressures in its Medicaid and Medicare businesses. Despite this, analysts maintain a "Moderate Buy" rating, expecting a 25% upside from current levels.
Elevance Health Outpaces Smaller Rival Selectis Health
This article compares Elevance Health (NYSE: ELV) and Selectis Health (OTCMKTS: GBCS), concluding that Elevance is a better long-term investment due to its larger size, stronger financials, and greater institutional support. It highlights the competitive advantage of scale and financial strength in the healthcare industry, noting Elevance's higher revenue, earnings, profitability, and lower stock volatility compared to Selectis Health.
Lawson Kroeker Investment Management Inc. NE Has $7.09 Million Stock Holdings in Elevance Health, Inc. $ELV
Lawson Kroeker Investment Management Inc. NE significantly reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 53.3%, now holding 20,212 shares valued at $7.09 million. Despite this reduction, Elevance Health remains the firm's 18th largest holding, comprising 2.1% of its portfolio. Elevance Health recently surpassed quarterly EPS expectations but slightly missed revenue estimates, while also increasing its quarterly dividend.
Aberdeen Group Boosts Elevance Health Holdings
Aberdeen Group plc, a major institutional investor, has increased its stake in Elevance Health, Inc. (NYSE: ELV) by 6.1% during the fourth quarter of 2025, now owning 288,976 shares valued at approximately $101 million. This move signals confidence in Elevance Health's long-term prospects as a leading health insurance provider in the U.S. Investors are now keenly awaiting Elevance Health's upcoming quarterly earnings report for further insights into the company's performance.
Aberdeen Group plc Increases Holdings in Elevance Health, Inc. $ELV
Aberdeen Group plc significantly increased its stake in Elevance Health, Inc. by 6.1% in the fourth quarter, now holding 288,976 shares valued at approximately $101.3 million. This comes after Elevance Health surpassed Q4 EPS estimates and raised its quarterly dividend. The company maintains a "Moderate Buy" rating from analysts with an average price target of $387.40.
Does Alignment Healthcare's (ALHC) Mixed Quarter Clarify or Cloud Its Medicare Advantage Scale Ambitions?
Alignment Healthcare (ALHC) reported a mixed quarter with 44.4% revenue growth and an EPS beat, yet issued weaker-than-expected revenue guidance, causing an 8.5% share price drop. The company continues to emphasize expanding its Medicare Advantage offerings and national footprint, supported by a recent US$256.2 million follow-on equity offering. This article explores how these results and future guidance impact the investment narrative, highlighting the balance between growth, profitability, and market risks.
Elevance expands out-of-network referral penalties to New York
Elevance Health is extending its out-of-network referral penalties to New York as of April 3, 2026, at 12:03 PM CDT. This move by the insurance giant indicates a broader application of its policies regarding healthcare providers outside its network. The article highlights the expansion of these penalties, impacting healthcare access and costs for New York residents with Elevance Health plans.
Elevance Health: Can the Stock Recover in 2026 after Last Year’s 30% Decline?
Elevance Health stock declined over 34% from its 52-week high due to a government-mandated enrollment freeze for its Medicare Advantage plans and lower-than-expected 2026 EPS guidance. Despite these challenges, the company has undertaken a significant senior leadership overhaul and reiterated its commitment to capital deployment, targeting at least 12% adjusted EPS growth in 2027. Wall Street analysts and TIKR's valuation model suggest significant upside potential, with a mean price target implying a 26.7% increase, contingent on a favorable resolution to regulatory issues and successful execution of its recovery strategy.
Elevance expands out-of-network referral penalties to New York
Elevance Health is expanding its out-of-network referral penalties to New York. This move is part of the company's broader strategy regarding healthcare costs and provider networks. The article reports on this specific geographical expansion of Elevance's policy.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elevance Health, Inc. (ELV) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elevance Health, Inc. (NYSE:ELV) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Elevance securities before April 18, 2024, and continue to hold them, to connect and assist with the investigation. The firm operates on a contingency fee basis for class action lawsuits.
Molina Healthcare, Inc. (MOH) stock price, news, quote and history
This page provides comprehensive information on Molina Healthcare, Inc. (MOH) stock, including its current price, historical data, financial performance, and analyst ratings. The stock closed at $134.03, down 3.44%, with recent news highlighting its Q4 earnings, a 55% one-year share price fall, and a new position by billionaire Seth Klarman. The company operates in healthcare plans, primarily serving low-income families through Medicaid, Medicare, and state insurance marketplaces.
Stock Sector Outlooks: Morningstar’s Top Q2 Picks Across the Market
Morningstar analysts provide their sector outlooks and top stock picks for the second quarter of 2026. The article covers various sectors including Technology, Communication Services, Utilities, Consumer Cyclicals, Financial Services, Real Estate, Consumer Defensives, Energy, Basic Materials, Industrials, and Healthcare. Each sector overview discusses recent performance and highlights specific companies Morningstar favors.
CVS Pharmacy's Digital Health Innovations Drive Strategic Growth in North American Retail Pharmacy S
CVS Pharmacy is solidifying its leadership in the North American retail pharmacy sector through significant digital health innovations and expanded clinical services, including enhanced app-based prescription management, MinuteClinic virtual care, and AI integration. These strategic moves position CVS for continued growth by meeting evolving consumer demands for convenient and affordable healthcare. The company's resilience, driven by integrated care models and robust market share gains, makes it an attractive option for investors seeking stable revenue streams in the healthcare sector.
HF Advisory Group LLC Increases Stock Position in Elevance Health, Inc. $ELV
HF Advisory Group LLC significantly increased its stake in Elevance Health (NYSE: ELV) by 1,797% in Q4, acquiring an additional 144,655 shares to hold a total of 152,705 shares valued at approximately $53.53 million, making it their 7th largest holding. This comes as Elevance Health exceeded Q4 EPS estimates with strong revenue growth, raised its quarterly dividend, and maintains a "Moderate Buy" analyst rating. The company also reported solid financial metrics including a market cap of $65.68 billion and a P/E ratio of 11.90.
Cigna posts Q1 results by 6:30 a.m. ET, holds investor call April 30
The Cigna Group (NYSE: CI) announced it will release its first quarter 2026 financial results on April 30, 2026, by 6:30 a.m. ET. Management will host a conference call to discuss these results at 8:30 a.m. ET, with a live webcast and replay available. This announcement continues the company's established practice of pre-announcing earnings logistics, with historical data showing an average -5.52% stock move following previous earnings-tagged events, despite often positive fundamentals.
Humana (HUM) Valuation Check As Shares Face Ongoing Medicare Advantage Regulatory Pressure
Humana (HUM) shares have faced a significant decline over the past year, trading at $176.95, which is below its fair value estimate of $212.87. This undervaluation is largely due to increasing regulatory pressure on Medicare Advantage, a key growth driver for the company. The valuation is dependent on how well Medicare Advantage profitability holds up against new rules and the potential for audit repayments.
AI Investing Insights - Official Homepage - Intellectia AI™
This page from Intellectia AI provides news and events for the IYH stock, an iShares U.S. Healthcare ETF. It displays current and after-market pricing, along with recent headlines from sources like NASDAQ.COM, SeekingAlpha, and Benzinga, covering significant ETF withdrawals, acquisition news, and healthcare sector developments. The platform positions itself as a trusted AI tool for winning trades.
Healthcare: Increased Clarity on Drug Pricing and Tariffs Led to a Rebound in Q1
The Morningstar Healthcare Index, after lagging due to drug pricing uncertainty and tariffs, is expected to see solid performance in 2026, driven by its defensive nature, innovation, and benefits from AI. The sector is considered undervalued overall, with healthcare plans and devices looking most attractive. AI is anticipated to significantly reduce the time required to bring new pharmaceuticals to market, benefiting biopharma.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Elevance Health (ELV)
Analysts have issued conflicting ratings for healthcare companies Pfizer (PFE) and Elevance Health (ELV). Pfizer received a "Hold" rating from Bernstein and Citi, with a consensus price target indicating a modest upside. Elevance Health was rated "Buy" by both Bernstein and Cantor Fitzgerald, with a consensus price target suggesting a significant upside.
Elevance sidesteps Medicare Advantage sanctions for now
Elevance Health has been granted an extension by the CMS to correct faulty risk adjustment data submissions for its Medicare Advantage plans, thereby avoiding immediate sanctions. The insurer now has until May 30, 2026, to comply with federal data reporting requirements stretching back seven years. Failure to meet this new deadline could result in severe penalties, including a suspension of new member enrollments for its non-compliant MA plans.
Elevance Health Inc. stock outperforms competitors on strong trading day
Shares of Elevance Health Inc. (ELV) increased by 1.96% to $298.50 on Wednesday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also rise. This marks the stock's second consecutive day of gains. The positive performance occurred during a strong trading session for the stock market overall.
Leerink sees UnitedHealth stock facing largest RADV audit exposure
Leerink's report indicates that the Centers for Medicare & Medicaid Services (CMS) is significantly expanding its 2020 Risk Adjustment Data Validation (RADV) audits, reviewing 470 Medicare Advantage contracts compared to 58 in 2018. UnitedHealth Group (NYSE:UNH) faces the most substantial exposure, with 60 contracts covering 92% of its 2020 Medicare Advantage membership under review. All publicly traded Medicare Advantage plans are included in these expanded audits, which will begin processing in April 2025.
Rockland Trust Co. Purchases 63,538 Shares of Elevance Health, Inc. $ELV
Rockland Trust Co. significantly increased its stake in Elevance Health (NYSE:ELV) by 8,251.7%, purchasing 63,538 shares to bring its total holdings to 64,308 shares, valued at approximately $22.54 million. This move comes as Elevance Health reported Q4 EPS of $3.33, exceeding analyst expectations, and projected FY 2026 guidance at $25.50 EPS. The company maintains a "Moderate Buy" consensus rating from analysts with an average target price of $387.40, and also recently increased its quarterly dividend to $1.72 per share.
eHealth Board Member Andrea Brimmer to Step Down
Andrea Brimmer, a long-serving board member of eHealth, Inc., will be stepping down from her position when her current term expires on June 18, 2026. Brimmer has been a valued member for nearly eight years, and her departure signifies a transition for the online health insurance marketplace as it navigates an evolving industry landscape. While CEO Derrick Duke expressed gratitude for her contributions, the company will need to identify a new board member to fill the role.
J. Safra Sarasin Holding AG Sells 9,116 Shares of Elevance Health, Inc. $ELV
J. Safra Sarasin Holding AG significantly reduced its stake in Elevance Health, selling 9,116 shares and cutting its holdings by 63.3%. Despite this, Elevance Health reported strong Q4 EPS, beating consensus, and increased its quarterly dividend. The stock currently holds a "Moderate Buy" consensus rating from analysts, although several recent downgrades have occurred.
CVS Specialty delivers personalized care through 30+ Centers of Excellence
CVS Specialty leverages over 30 condition and therapy-specific Centers of Excellence (CoEs) to provide personalized care for patients with complex, rare, and ultrarare conditions. These CoEs feature specially trained CareTeams, deep clinical expertise, and systems to ensure medication access and support for unpredictable patient needs, as highlighted by the case of a young hemophilia patient. The model aims to simplify care by addressing the unique challenges and varying needs of patients within a broad spectrum of chronic conditions.
Elevance Health Inc (ELV) Shares Up 2.57% on Mar 31
Elevance Health Inc (ELV) shares rose by 2.57% on March 31, reaching an intraday high of $295.17 before closing at $292.12. This places the stock significantly below its 52-week high but above its 52-week low. Wall Street analysts predict an average target price of $385.02 for ELV, suggesting a potential upside of 31.80%, while GuruFocus estimates a one-year GF Value of $571.80, implying a 95.74% upside.
Elevance Health Inc. stock rises Tuesday, still underperforms market
Elevance Health Inc. (ELV) saw its stock rise by 2.80% to $292.75 on Tuesday, breaking a three-day losing streak. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index climbed 2.91% and the Dow Jones Industrial Average increased by 2.49%.
Elevance fills slew of mid-level leadership positions
Elevance has announced several mid-level executive appointments, particularly within its health benefits division and its Carelon health services division. These leadership changes aim to improve execution and support growth, especially in Carelon, which has been a strong performer amidst struggling profits in the core health benefits division. New roles include Carelon's first chief growth and strategy officer and new presidents and CFOs across both segments.
New Carelon chiefs will oversee services for 90 million consumers
Elevance Health has announced leadership appointments across its Health Benefits and Carelon organizations to strengthen execution and drive growth. These changes are intended to better align capabilities, accelerate decision-making, and improve enterprise efficiency for Carelon, which serves over 90 million consumers. The new appointments include leaders for Government Business, Carelon Health, Carelon Insights, and Chief Growth and Strategy Officer and CFO roles for Carelon and Health Benefits.
Elevance Health reshuffles leadership at Carelon, insurance units
Elevance Health has announced a leadership reshuffle within its Carelon and insurance units. The article, authored by Nona Tepper, was published on March 31, 2026, at 10:42 AM CDT. Further details about the specific changes were not provided in the snippet.
Bright Rock Capital Management LLC Makes New Investment in Elevance Health, Inc. $ELV
Bright Rock Capital Management LLC has made a new investment in Elevance Health, Inc. (NYSE:ELV) by acquiring 21,000 shares valued at approximately $7.36 million, making it their 27th largest position. The company reported strong Q4 EPS of $3.33, exceeding estimates, and raised its quarterly dividend to $1.72 per share. Despite mixed analyst ratings, the stock holds a "Moderate Buy" consensus with an average target price significantly above its current trading price.
Short Interest in Elevance Health, Inc. (NYSE:ELV) Drops By 13.2%
Elevance Health, Inc. (NYSE:ELV) experienced a 13.2% drop in short interest during March, with total short interest moving to 3,669,028 shares as of March 13th. The days-to-cover ratio for ELV is currently 1.2 days, and hedge funds have significantly adjusted their holdings in the company. Elevance Health recently surpassed analyst earnings estimates for its quarterly report, announced an increased quarterly dividend, and received a "Moderate Buy" consensus rating from analysts.
Elevance Health, Inc. Trade Ideas — HAM:A58
This article compiles various trading ideas for Elevance Health, Inc. (HAM:A58, NYSE:ELV) from multiple analysts on TradingView. The analyses present both bullish and bearish outlooks, with strategies ranging from long positions targeting upside breakouts to short positions based on resistance levels and potential corrections. The ideas incorporate technical indicators like ascending triangles, RSI, and Fibonacci retracements, alongside fundamental data such as earnings beats and PEG ratios.
Elevance Health Leads in Trading Volume Amid Diverging Institutional Investments
Elevance Health (ELV) recently showed the highest trading volume despite a small loss, with institutional investors holding a significant portion of shares. While some investors reduced their stake, others increased theirs, reflecting mixed sentiment. The company's strong financial performance, including solid EPS and a raised dividend, solidifies its appeal amidst cautious analyst outlooks due to broader economic and sector risks.
Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2026 Results on April 22, 2026
Elevance Health will host a conference call and webcast on April 22, 2026, at 8:30 a.m. EDT, to discuss its first quarter 2026 financial results, which will be released at 6:00 a.m. EDT on the same day. A webcast replay will be available until May 22, 2026. The company serves approximately 104 million consumers and aims to improve health as a trusted partner.
Elevance Health posts Q1 results April 22, webcast at 8:30 a.m.
Elevance Health (NYSE: ELV) announced it will release its first-quarter 2026 financial results on April 22, 2026, at 6:00 a.m. EDT. Following the release, management will host a conference call and webcast at 8:30 a.m. EDT to discuss the results and outlook. A replay of the webcast will be available until May 22, 2026.
